Thomson Sally E, McLennan Susan V, Kirwan Paul D, Heffernan Scott J, Hennessy Annemarie, Yue Dennis K, Twigg Stephen M
Discipline of Medicine, University of Sydney, Sydney, Australia.
J Diabetes Complications. 2008 Jul-Aug;22(4):284-94. doi: 10.1016/j.jdiacomp.2007.07.001. Epub 2008 Apr 16.
Diabetic renal disease is characterized by accumulation of extracellular matrix, glomerulosclerosis, and tubulointerstitial fibrosis. Connective tissue growth factor (CTGF) is implicated in these changes, as it contributes to new matrix synthesis and is increased in the diabetic kidney. CTGF also inhibits mesangial matrix degradation through up-regulation of the tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). In a non-human primate model of diabetes, we determined whether the level of renal CTGF protein before development of albuminuria correlated with renal matrix and TIMP-1 changes and whether renal CTGF predicts progression to albuminuria.
In a group of diabetic (n=9) and control (n=6) baboons after a 5-year duration of diabetes, renal tissue CTGF and TIMP-1 were detected by immunohistochemistry and compared with glomerular basement membrane (GBM) thickness and mesangial volume measurements from electron photomicrographs of renal biopsies. Urinary albumin levels were measured at 5 and 10 years of diabetes.
GBM thickness, CTGF protein, and TIMP-1 protein were increased after 5 years of diabetes (each P<.05). Tubular fibronectin scores correlated with tubular CTGF scores (r=0.72, P=.002). In diabetic animals, GBM thickness correlated with tubular and total CTGF levels (P=.002 and P=.04, respectively), whereas mesangial cell and total matrix volume correlated with glomerular TIMP-1 (P=.02 and P=.01, respectively). Tubular CTGF scores (P=.008) and GBM thickness (P=.03) at 5 years in diabetes each predicted the degree of albuminuria at 10 years.
These results suggest that early increases in renal CTGF protein contribute to incipient diabetic nephropathy and that renal CTGF may have utility as an early marker for progression to dysfunction in the diabetic kidney.
糖尿病肾病的特征是细胞外基质积聚、肾小球硬化和肾小管间质纤维化。结缔组织生长因子(CTGF)与这些变化有关,因为它有助于新基质的合成,并且在糖尿病肾脏中含量增加。CTGF还通过上调基质金属蛋白酶1组织抑制剂(TIMP-1)来抑制系膜基质降解。在糖尿病的非人类灵长类动物模型中,我们确定蛋白尿发生前肾CTGF蛋白水平是否与肾基质和TIMP-1变化相关,以及肾CTGF是否可预测蛋白尿的进展。
在一组患糖尿病5年的糖尿病(n=9)和对照(n=6)狒狒中,通过免疫组织化学检测肾组织CTGF和TIMP-1,并与肾活检电子显微镜照片中肾小球基底膜(GBM)厚度和系膜体积测量值进行比较。在糖尿病5年和10年时测量尿白蛋白水平。
糖尿病5年后GBM厚度、CTGF蛋白和TIMP-1蛋白增加(均P<0.05)。肾小管纤连蛋白评分与肾小管CTGF评分相关(r=0.72,P=0.002)。在糖尿病动物中,GBM厚度与肾小管和总CTGF水平相关(分别为P=0.002和P=0.04),而系膜细胞和总基质体积与肾小球TIMP-1相关(分别为P=0.02和P=0.01)。糖尿病5年时的肾小管CTGF评分(P=0.008)和GBM厚度(P=0.03)均可预测10年时的蛋白尿程度。
这些结果表明,肾CTGF蛋白的早期增加促成了早期糖尿病肾病,并且肾CTGF可能作为糖尿病肾脏功能障碍进展的早期标志物。